Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 12/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999572 | 0.94 | CA12 (0.51) | CA12CA1CA2CA9ACHE | |
| SCHEMBL25181487 | 0.92 | CA12 (0.59) | CA12CA1CA2CA9ACHE | |
| SCHEMBL31284031 | 0.92 | CA12 (0.59) | CA12CA1CA2CA9ACHE | |
| SCHEMBL5267079 | 0.88 | DGKA (0.57) | CA12CA1CA2CA9ACHE | |
| SCHEMBL20589930 | 0.88 | CA12 (0.59) | CA12CA1CA2CA9ACHE | |
| SCHEMBL31065300 | 0.88 | CA12 (0.55) | CA12CA1CA2CA9ACHE | |
| SCHEMBL12999531 | 0.88 | TDP1 (0.47) | CA12CA1CA2CA9ACHE | |
| SCHEMBL15613905 | 0.87 | CA12 (0.54) | CA12CA1CA2CA9ACHE | |
| SCHEMBL5265859 | 0.86 | NAAA (0.53) | CA12CA1CA2CA9ACHE | |
| SCHEMBL34462671 | 0.86 | CA12 (0.43) | CA12CA1CA2CA9ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | FLNB, FLNA, FSCN1 | CA12 3878/4885CA1 3299/4885CA2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.